CCRK Activators
The chemical class of CCRK activators is characterized by a range of compounds that indirectly influence the activity of CCRK, primarily through modulation of cell cycle kinases and related signaling pathways. This group includes various cyclin-dependent kinase inhibitors, such as Olomoucine, Roscovitine, Flavopiridol, and PD0332991 (Palbociclib), which exert their influence by targeting key regulators of the cell cycle. By modulating the activity of these kinases, these compounds indirectly affect the functional landscape in which CCRK operates, thereby potentially influencing its activity.
These inhibitors, including Voruciclib, Dinaciclib, and AZD5438, showcase the interconnected nature of kinase signaling in cell cycle regulation and the indirect pathways through which CCRK activity can be modulated. Compounds like CR8 and Milciclib, with their broad-spectrum inhibitory action on CDKs, further highlight the complex network of kinases that govern cell cycle progression and the potential for indirect modulation of CCRK. Selective inhibitors such as R547 and Ribociclib, targeting specific CDKs, and SNS-032, affecting transcription regulation, also illustrate the indirect mechanisms by which CCRK activity can be influenced.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
A cyclin-dependent kinase inhibitor; can indirectly influence CCRK activity by modulating cell cycle progression and kinases regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Another CDK inhibitor; potentially affects CCRK by altering the balance of cell cycle-associated kinases. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
A broad-spectrum CDK inhibitor; might indirectly modulate CCRK activity through its impact on cell cycle progression and transcriptional regulation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A selective inhibitor of CDK4/6; can indirectly affect CCRK through cell cycle regulation and kinases interaction. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
A potent CDK inhibitor; could modulate CCRK activity indirectly by influencing the broader cell cycle kinase network. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
Inhibits CDK1, 2, and 9; can affect CCRK indirectly through modulation of cell cycle progression and transcription factors. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
A multi-CDK inhibitor; potentially modulates CCRK through its effects on cell cycle progression and kinase signaling. | ||||||
R547 | 741713-40-6 | sc-364596 sc-364596A | 2 mg 5 mg | $375.00 $395.00 | ||
A selective CDK inhibitor; can influence CCRK indirectly by modulating kinases involved in cell cycle control. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
Targets CDK2, 7, and 9; could affect CCRK indirectly through alterations in cell cycle and transcription regulation. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
A CDK4/6 inhibitor; may indirectly influence CCRK activity via its role in cell cycle regulation and kinase interaction. | ||||||